HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland

<p>Abstract</p> <p>Background</p> <p>HIV integrase inhibitor use is limited by low genetic barrier to resistance and possible cross-resistance among representatives of this class of antiretrovirals. The aim of this study was to analyse integrase sequence variability amo...

Full description

Bibliographic Details
Main Authors:	Parczewski Miłosz, Bander Dorota, Urbańska Anna, Boroń-Kaczmarska Anna
Format:	Article
Language:	English
Published:	BMC 2012-12-01
Series:	BMC Infectious Diseases
Subjects:	HIV-1 Integrase inhibitors Raltegravir Antiretroviral treatment failure Drug resistance mutations
Online Access:	http://www.biomedcentral.com/1471-2334/12/368

Similar Items

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01)

HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY
by: V. I. SHAKHGILDYAN
Published: (2017-05-01)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
by: Damond Florence, et al.
Published: (2011-08-01)

Resistance to inhibitors of the human immunodeficiency virus type 1 integration
by: Daria J Hazuda

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
by: Vogel Martin, et al.
Published: (2009-11-01)

Novel therapeutic strategies targeting HIV integrase
by: Quashie Peter K, et al.
Published: (2012-04-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

Are new antiretroviral treatments increasing the risks of clinical obesity?
by: Andrew Hill, et al.
Published: (2019-01-01)

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
by: Lucas de Almeida Machado, et al.
Published: (2019-09-01)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
by: Linda A. Mandikiyana Chirimuta, et al.
Published: (2022-10-01)

Drug-selective pressure effect on HIV integrase mutations in antiretroviral naïve and experienced patients
by: Parya Basimi, et al.
Published: (2023-04-01)

Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women
by: Diego M. Cecchini, et al.
Published: (2017-06-01)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
by: Aurelio Orta-Resendiz, et al.
Published: (2020-02-01)

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
by: Michał S. Barski, et al.
Published: (2019-08-01)

Resistance to Integrase Inhibitors
by: Mathieu Métifiot, et al.
Published: (2010-06-01)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
by: José Ramón Santos, et al.
Published: (2023-06-01)

Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling
by: Van der Borght Koen, et al.
Published: (2013-01-01)

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial
by: Borja Mora-Peris, et al.
Published: (2021-12-01)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
by: Kaiming Tao, et al.
Published: (2023-09-01)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01)

HIV drug resistance against strand transfer integrase inhibitors
by: Kaitlin Anstett, et al.
Published: (2017-06-01)

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA
by: Elamin H. Elbasha, et al.
Published: (2015-09-01)

Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis
by: Jennifer L Elliott, et al.
Published: (2020-09-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function
by: Matthew R. Singer, et al.
Published: (2023-02-01)

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis
by: Ke Zhang, et al.
Published: (2021-07-01)

Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors
by: Parmit Kumar Singh, et al.
Published: (2022-08-01)

Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018
by: Lan Y, et al.
Published: (2020-12-01)

HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis.
by: Miłosz Parczewski, et al.
Published: (2012-01-01)

Multimodal Functionalities of HIV-1 Integrase
by: Alan N. Engelman, et al.
Published: (2022-04-01)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
by: Annalisa Mondi, et al.
Published: (2022-03-01)

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients
by: Maria Saumoy, et al.
Published: (2021-08-01)

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
by: Rossana Scutari, et al.
Published: (2020-03-01)

The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy
by: Sara Rodrigues Fernandes, et al.
Published: (2023-08-01)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
by: Pratibha C Koneru, et al.
Published: (2019-05-01)

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China
by: Weiguang Fan, et al.
Published: (2022-09-01)

New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis
by: Violet Dismas Kajogoo, et al.
Published: (2023-03-01)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
by: Emma G. Foster, et al.
Published: (2022-12-01)

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
by: Kirsten L. White, et al.
Published: (2014-07-01)